| Literature DB >> 28464848 |
Sophie Faulkner1,2, Penny Bee3.
Abstract
BACKGROUND: Sleep problems are very common in people with schizophrenia spectrum disorders, and impact negatively on functioning and wellbeing. Research regarding interventions to improve sleep in this population has been lacking. Little is known regarding these patient's perspectives on sleep problems and their treatment, providing very little foundation on which to develop acceptable and patient-centred treatments.Entities:
Keywords: Antipsychotic; Circadian rhythm disorder; Daytime functioning; Insomnia; Interpretive phenomenological analysis; Interview; Psychosis; Qualitative; Schizophrenia; Sleep
Mesh:
Substances:
Year: 2017 PMID: 28464848 PMCID: PMC5414297 DOI: 10.1186/s12888-017-1329-8
Source DB: PubMed Journal: BMC Psychiatry ISSN: 1471-244X Impact factor: 3.630
Fig. 1The analysis process
Demographic and clinical information
|
| ||
|---|---|---|
| Psychiatric diagnosis: | Schizophrenia | 8 |
| Schizoaffective disorder | 6 | |
| Delusional disorder | 1 | |
| Current level of support: | Independent accommodation, outpatient care | 2 |
| Independent accommodation, community team | 8 | |
| Independent accommodation, daily support | 2 | |
| Supported accommodation | 1 | |
| Acute mental health ward | 2 | |
| Psychotropic medications prescribed: | Hypnotics | 1 |
| Mood stabilisers | 5 | |
| Anti-depressants | 9 | |
| At least one antipsychotic | 15 | |
| One antipsychotic | 8 | |
| Two antipsychotics | 7 | |
| Oral antipsychotics, no depota | 11 | |
| Depot and oral antipsychotics | 3 | |
| Depot antipsychotic, no oral antipsychotic | 1 | |
| Clozapineb | 2 | |
| Antipsychotic dosage (as a fraction of DDDc) | Range | 0.36–5.5 |
| Median / mean (SDd) | 2 / 2.19 (1.28) | |
| Gender: | % male | 67% |
| Age: | Range | 23–69 years |
| Median / mean (SD) | 44 / 45.9 (10.55) | |
| GAF-F score (functioning)e: | Range | 38–85 |
| Median / mean (SD) | 65 / 62.3 (12.16) | |
| GAF-S score (symptoms)e: | Range | 21–80 |
| Median / mean (SD) | 39/ 47.7 (19.40) | |
aLong-acting intramuscular injection, typically given every 1–4 weeks. bSpecified separately as only used in otherwise treatment resistant illness. cThe defined daily dose (DDD) is the assumed average maintenance dose per day for a drug used for its main indication in adults. [98] dStandard Deviation. eScores may range from 1 to 100, lower scores = more impairment
PSQI scores and individual PSQI question answers
| Respondent | Self reported average sleep duration: hrs | Self reported sleep latency: minutes | During the past month, how often have you taken medicine to help you sleep (prescribed or “over the counter”)?a | Total PSQI scoreb |
|---|---|---|---|---|
| r01 | 11 | 60 | Not during the past month (0) | 3 |
| r02 | 4.5 | 3 | Three or more times a week (3) | 12 |
| r03 | 12 | 10 | Three or more times a week (3) | 6 |
| r04 | 6 | 60 | Not during the past month (0) | 2 |
| r05 | 14.5 | 180 | Not during the past month (0) | 8 |
| r06 | 6.5 | 60 | Not during the past month (0) | 10 |
| r07 | 4 | 120 | Three or more times a week (3) | 15 |
| r08 | 8.5 | 20 | Three or more times a week (3) | 7 |
| r09 | 11 | 30 | Not during the past month (0) | 7 |
| r10 | 4.5 | 30 | Three or more times a week (3) | 18 |
| r11 | 8 | 30 | Not during the past month (0) | 4 |
| r12 | 3 | 180 | Not during the past month (0) | 13 |
| r13 | 8 | 60 | Three or more times a week (3) | 9 |
| r14 | 9 | 10 | Not during the past month (0) | 3 |
| r15 | 7 | 60 | Three or more times a week (3) | 13 |
| Median / mean | 8 / 7.83 | 60 / 61 | 8 / 8.7 |
aEach question can score between 0 (best) and 3 (worst)
bScores can range from = 0 (best possible), to = 21 (worst possible), although in practice scoring 3 in all areas would be very unusual even amongst those with severe sleep problems. Interpretation guidance suggests scores of >5 indicate poor sleep quality [40]